

December 26, 2012

BD Completes Acquisition of Safety Syringes, Inc.

FRANKLIN LAKES, N.J., Dec. 26, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has completed its acquisition of Safety Syringes, Inc., a privately held California-based company that specializes in the development of anti-needlestick devices for prefilled syringes. The financial terms were not disclosed.

The acquisition broadens BD's healthcare worker safety offering to include passive safety technologies for any prefillable syringe customer.

"We believe the Safety Syringes product line is a valuable asset to BD and aligns well with our focus on healthcare worker safety, and offering higher-value products," said Claude Dartiguelongue, President, BD Medical - Pharmaceutical Systems. "We are excited about this acquisition, which expands the Company's presence in safety technologies and further demonstrates BD's commitment to developing innovative solutions that help address our customers' unmet needs. We are pleased to welcome this new product portfolio and these new associates to BD."

BD expects the transaction to be minimally dilutive for fiscal year 2013, and does not expect it to impact BD's previously communicated 2013 earnings guidance.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contacts:

Colleen T. White, Corporate Communications – 201-847-5369; colleen_white@bd.com
Monique N. Dolecki, Investor Relations – 201-847-5378; monique_dolecki@bd.com

SOURCE BD (Becton, Dickinson and Company)